Wertpapierdatensatz · archiviertes Quartal
ZVRA
Zevra Therapeutics, Inc. · Healthcare · Biotechnology
16Erfasste Halter
+2Δ Inhaber
19.14MGehaltene Aktien
$181.99MGemeldeter Wert
+2Neue Positionen
−0Ausstiege
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +14.3% ·
Aktienfluss -0.8% ·
neue Nettopositionen +12.5%
— Formel
Eigentümerfragmentierung — mehr Halter, kleinere Gesamtbeteiligung
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q3 2025
Beteiligung im Zeitverlauf
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | +6 | 29.05M | $415.89M | +12 | −6 |
| Q1 2026 | 69 | 0 | 26.10M | $242.75M | +4 | −4 |
| Q4 2025 | 68 | +1 | 25.36M | $227.23M | +1 | — |
| Q3 2025 | 16 | +2 | 19.14M | $181.99M | +2 | — |
| Q2 2025 | 11 | 0 | 17.09M | $150.53M | — | — |
| Q1 2025 | 8 | 0 | 6.58M | $49.25M | +1 | −1 |
| Q4 2024 | 8 | +1 | 6.30M | $52.58M | +2 | −1 |
| Q3 2024 | 6 | +2 | 1.92M | $13.36M | +3 | −1 |
| Q2 2024 | 4 | — | 1.15M | $5.62M | — | — |
Wer es hält · Q3 2025
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passiv) | 4.04M | -1.1% | $38.39M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | The Vanguard Group ✦ (passiv) | 3.08M | +4.4% | $29.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | The Vanguard Group ✦ (passiv) | 3.08M | +4.4% | $29.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passiv) | 3.08M | +4.4% | $29.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 2.23M | -46.6% | $21.16M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 1.63M | -28.6% | $15.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passiv) | 1.43M | +14.9% | $13.57M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passiv) | 1.30M | +4.7% | $12.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passiv) | 1.30M | +4.7% | $12.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Millennium Management ✦ | 1.04M | +63.1% | $9.85M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Marshall Wace ✦ | 912.30K | Neu | $8.68M | 0.0% | New | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 912.30K | Neu | $8.68M | 0.0% | New | 1 | SEC ↗ |
| 23 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 877.97K | — | $8.35M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Goldman Sachs Group ✦ | 761.78K | — | $7.24M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Goldman Sachs Group ✦ | 761.78K | — | $7.24M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | D. E. Shaw & Co. ✦ | 725.83K | +283.4% | $6.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 32 | D. E. Shaw & Co. ✦ | 725.83K | +283.4% | $6.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 33 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | Morgan Stanley ✦ | 555.95K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | Citadel Advisors ✦ | 191.80K | +67.8% | $1.82M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 40 | Wellington Management ✦ | 187.27K | +28.0% | $1.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 41 | Wellington Management ✦ | 187.27K | +28.0% | $1.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 42 | Wellington Management ✦ | 187.27K | +28.0% | $1.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 43 | AQR Capital Management ✦ | 152.31K | Neu | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 44 | AQR Capital Management ✦ | 152.31K | Neu | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 45 | AQR Capital Management ✦ | 152.31K | Neu | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 46 | AQR Capital Management ✦ | 152.31K | Neu | $1.45M | 0.0% | New | 1 | SEC ↗ |
| 47 | T. Rowe Price ✦ | 28.49K | +10.9% | $271,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Marshall Wace | $8.68M | 0.0% |
| Marshall Wace | $8.68M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
| AQR Capital Management | $1.45M | 0.0% |
Ausgestiegen
| Keine erfassten Ausstiege in diesem Quartal. |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 147 Inhaber, 40.93M Anteile, $378.34M gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Häufig gemeinsam gehalten
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Herkunft: Beteiligung aus geparsten 13F-Common-Stock-Positionen (verfolgte Grundgesamtheit, vergleichbare Sets für Veränderungen); Insider-Zeilen aus Formularen 3/4/5; Beteiligungen aus Schedules 13D/13G; jede Einreichung verlinkt auf das Original auf SEC EDGAR.
Berichtszeitraum: Q3 2025 ·
Methodik ·
Über die API abrufen